VX-702: Highly Selective ATP-Competitive p38α MAPK Inhibitor for Inflammation Research

Executive Summary: VX-702 (SKU: A8687, APExBIO) is a potent and highly selective inhibitor of p38α MAPK (MAPK14) with an IC₅₀ range of 4–20 nM under in vitro kinase assay conditions. It acts as an ATP-competitive inhibitor, stabilizing an inactive kinase conformation that facilitates dephosphorylation by PPM-type phosphatases, as demonstrated in recent crystallographic studies (Stadnicki et al., 2024). VX-702 suppresses the production of pro-inflammatory cytokines IL-6, IL-1β, and TNFα in LPS-primed human blood ex vivo. Preclinical studies show efficacy in collagen-induced arthritis and myocardial ischemia-reperfusion injury models, with oral bioavailability and favorable pharmacokinetics. The compound is not suitable for diagnostic or therapeutic use in humans and is intended for research applications only (APExBIO).

Biological Rationale

The p38 mitogen-activated protein kinase (MAPK) pathway, specifically the p38α isoform (MAPK14), regulates cellular responses to pro-inflammatory cytokines, environmental stress, and tissue injury (Stadnicki et al., 2024). Dysregulation of p38α MAPK signaling has been implicated in autoimmune diseases such as rheumatoid arthritis, as well as in acute coronary syndromes. As a key convergence point in inflammatory signaling, p38α MAPK controls the transcription and release of cytokines including IL-6, IL-1β, and TNFα. Inhibiting p38α MAPK thus represents a targeted strategy for modulating inflammation without broadly suppressing immune function. The high conservation of kinase ATP-binding sites necessitates selective inhibitors to minimize off-target effects (see Introduction).

Mechanism of Action of VX-702, P38α MAPK inhibitor, highly selective and ATP-competitive

VX-702 is a next-generation, highly selective, and ATP-competitive inhibitor of p38α MAPK. It binds with nanomolar affinity (IC₅₀: 4–20 nM, kinase buffer, 25–30°C) to the ATP-binding pocket of MAPK14, stabilizing an inactive conformation of the activation loop (Stadnicki et al., 2024; Fig. 2A). This conformation exposes the phospho-threonine residue, enhancing accessibility to PPM-type phosphatases (e.g., WIP1) and accelerating kinase dephosphorylation. This dual action—direct inhibition and dephosphorylation promotion—distinguishes VX-702 from earlier p38 inhibitors which lacked this mechanism. VX-702 does not cause significant inhibition of related kinases (e.g., ERK, JNK) at concentrations under 1 μM, reflecting its improved selectivity profile. The compound is orally bioavailable and demonstrates linear pharmacokinetics in animal models (Results; Table 1).

Evidence & Benchmarks

• VX-702 inhibits recombinant human p38α MAPK (MAPK14) with an IC₅₀ of 4–20 nM under in vitro kinase assay conditions (20 mM HEPES, pH 7.5, 25°C) (Stadnicki et al., 2024, Table 1).
• VX-702 suppresses LPS-induced release of IL-6, IL-1β, and TNFα in human blood ex vivo at concentrations as low as 100 nM (Supplementary Data).
• In collagen-induced arthritis mouse models, oral VX-702 (10–30 mg/kg/day) reduces paw swelling and joint erosion comparably to methotrexate and prednisolone (Results: In vivo efficacy).
• VX-702 preserves mitochondrial and metabolic integrity of stored platelets in vitro and restores function after agitation interruption, with no induction of aggregation or calcium flux (Methods: Platelet assays).
• In isolated perfused rat kidney, VX-702 displays linear renal elimination and reabsorption, without significant interaction with organic anion or cation transporters (1–10 μM) (Pharmacokinetics).
• Crystallographic analysis reveals that VX-702-bound p38α adopts a flipped activation loop conformation, increasing dephosphorylation rate by PPM phosphatases relative to the apo form (Fig. 3B).
• VX-702 does not significantly inhibit ERK or JNK in cell-based assays at ≤1 μM (Selectivity Profile).

This article updates and extends the mechanistic detail provided in "VX-702: Selective p38α MAPK Inhibition for Advanced Inflammation Research" by highlighting recent structural findings on dual-action inhibition and dephosphorylation. For practical laboratory guidance, see "Optimizing Inflammation Research with VX-702", which details assay setup considerations. For a broader context of kinase inhibitor development, refer to "VX-702: Next-Generation Selective p38α MAPK Inhibitor in Inflammation and Cardiovascular Research".

Applications, Limits & Misconceptions

VX-702 is validated for use in cellular and animal models of inflammation, particularly for studying cytokine signaling and joint or cardiac injury. Its dual-action mechanism allows for evaluation of both kinase inhibition and phosphatase-driven dephosphorylation. It is not approved for human therapeutic or diagnostic use and is not suitable for use in clinical settings.

Common Pitfalls or Misconceptions

• VX-702 is not effective against non-p38 MAPK isoforms (e.g., p38β, γ, δ) at standard concentrations (≤1 μM), limiting its use to MAPK14-focused research.
• The compound does not function as a general anti-inflammatory and should not be used in place of non-selective immunosuppressants.
• VX-702 is insoluble in water; proper dissolution in DMSO or ethanol (with or without ultrasonication) is required for activity.
• It is intended strictly for in vitro or preclinical research and must not be used in humans or for diagnostic purposes.
• Long-term solution storage is not recommended due to potential compound degradation; use freshly prepared solutions.

Workflow Integration & Parameters

VX-702 is typically supplied as a solid by APExBIO and should be stored at −20°C. For experimental use, dissolve in DMSO (≥20.2 mg/mL) or ethanol (≥3.88 mg/mL with ultrasonication). Working concentrations in cell-based assays range from 10 nM to 1 μM. For animal studies, oral dosing between 10–30 mg/kg/day is documented. Solutions should be freshly prepared; do not store for extended periods. Ensure exclusion of water for dissolution. The product (A8687) is available from APExBIO for research applications only.

Conclusion & Outlook

VX-702, a highly selective and ATP-competitive p38α MAPK inhibitor, offers unique advantages for dissecting inflammatory signaling pathways and evaluating kinase-phosphatase crosstalk. Its dual mechanism of direct inhibition and promotion of dephosphorylation positions it as a valuable tool in preclinical models of arthritis, myocardial injury, and cytokine research (Stadnicki et al., 2024). Future studies may further exploit these mechanistic insights to develop more potent, selective, and therapeutically relevant kinase inhibitors. For advanced inflammation research, VX-702 remains a benchmark compound for selective MAPK14 inhibition.